Amlan International launches new natural alternatives to antibiotics


The elimination of antibiotics in feed from poultry and livestock production has left a huge void in protecting animals from the devastating effects of enteric disease. To help producers regain that protection, Amlan International, the animal health business of Oil-Dri Corporation of America, has launched two new natural products – Phylox Feed and NeutraPath – that help optimize gut health and economy. of production in the absence of antibiotics.

Phylox Feed is a natural alternative to coccidials and vaccines that can help growers increase their profitability. Coccidiosis, caused by Eimeria species, is an enteric disease that can have a significant economic impact on animal protein production. The synergistic blend of bioactive phytochemicals in Phylox works with multiple modes of action to damage Eimeria cell structure and function while supporting gut integrity and boosting immunity. Phylox can be effective for full-time or rotational use, and/or in a bio-shuttle program when resistance is an issue. Additionally, Phylox does not need to be removed from feed prior to slaughter. Phylox is an ideal solution for all poultry species, including broilers, egg layers and broiler breeders, all of which can be susceptible to fungal and bacterial toxins during growout and chicken production. eggs when exposed to faecal oocysts which are excreted during the coccidian cycle. . Research has shown that Phylox can be given at the same time as coccidial vaccines, preventing the spread of disease while immunity is developed by the bird without interfering with the effectiveness of the vaccine.

“The most important goal for producers is to keep animals healthy. Producers raise animals to a certain size, and they don’t want to lose them in the last days of their growth,” said Fred Kao, vice president of global sales for Amlan. “The launch of Phylox and NeutraPath will be a huge benefit to the animal protein industry. Animals can stay healthy and reach their full potential, naturally.

NeutraPath is a natural pathogen control product for antibiotic-free production that uses multiple modes of action to increase habitability and improve feed conversion. Using a proprietary, co-active blend of essential oils, fatty acids, and Amlan’s proprietary mineral technology, NeutraPath reduces pathogenic bacterial load and colonization, and improves gut health and structural integrity, which helps to improve performance and increase production yields.

“The management of enteric disease without antibiotics has put additional pressure on nutritionists and veterinarians to find natural solutions that can achieve the same level of performance seen with the use of antibiotics,” said Dr. Wade Robey, vice president of marketing and product development at Amlan. “NeutraPath has answered the call for a natural product that targets pathogens and the toxins they produce – and also improves gut health. It’s the natural alternative to antibiotics the animal protein industry has been waiting for. . »

NeutraPath can be used to protect the intestinal health of all species of livestock. the Journal of Animal Science recently published a study by UC Davis researchers on the effects of NeutraPath in weaned pigs with enterotoxin E.coli. NeutraPath reduced the incidence of severe diarrhea, improved feed efficiency during the final week of the study, and altered the diversity of fecal and ileal mucosal microbiota.

Both new products can be used individually or in a program with Amlan’s mineral-based products, such as Calibrin-Z and the Varium and NeoPrime patents, to help support gut health and improve productivity and efficiency.

Phylox and NeutraPath are commercially available in some international markets. Although not available for sale in the United States, North American customers interested in NeutraPath and Phylox can contact Amlan for more information on similar feed additives available in the United States that have been developed to optimize the intestinal health of production animals.


About Author

Comments are closed.